Nipah Vaccine “Factory” Concepts: What Current Research Supports
Description
Designing a Nipah “nanovaccine plant” touches three areas: which antigen/platform to produce, which expression system/bioreactor to use, and how to build a scalable downstream process under high biosafety.Designina scalable downstream process under high biosafety. system/bioreactor to use, and how to build a scalable downstream process under high biosafety.
Files
Steps to reproduce
Types of Nipah Vaccines Under Development Lead candidates use viral vectors (VSV-based, vaccinia LC16m8-based), live-attenuated NiV, virus-like particles (VLPs), multi-epitope subunits, and emerging mRNA–nanoparticle and G‑nanoparticle concepts 1456891115. Protection consistently targets surface glycoproteins G and F, which elicit neutralizing antibodies and full protection in hamsters and non‑human primates 148911. Expression Systems & “Green Factories” Mammalian cells (HEK293, Vero) are widely used for NiV VLPs and VSV/vaccinia vectors 1481319. Nicotiana benthamiana is validated as a rapid plant “bioreactor” for viral VLP vaccines (e.g., coronavirus IBV), offering fast, scalable, low‑contamination production via transient expression and agroinfiltration 1418. High‑yield fixed‑bed and perfusion bioreactors (scale‑X carbo, orbital shaken with ATF/TFF) can boost viral vaccine titers and reduce footprint, aligning with compact “plug‑and‑play” factories 1316. Downstream: Purification and Nano-/Particulate Formulation Scalable clarification → tangential flow filtration → chromatography → ultrafiltration/diafiltration workflows are established for large enveloped virus vectors and VLPs, preserving infectivity and achieving high purity 7131819. mRNA vaccines rely on lipid nanoparticles (LNPs) rather than chitosan, with detailed descriptions of upstream/downstream LNP-mRNA manufacturing and storage optimization 3. VLPs and nanoparticle antigens (e.g., 60‑mer G‑nanoparticle) provide multivalent, highly immunogenic display suitable for nasal or injectable formats 57818.